How to buy Arena Pharmaceuticals stock | $60.35

Arena Pharmaceuticals Inc is a biotechnology business based in the US. Arena Pharmaceuticals shares (ARNA) are listed on the NASDAQ and all prices are listed in US Dollars. Arena Pharmaceuticals employs 363 staff and has a trailing 12-month revenue of around 0.00.

Arena Pharmaceuticals stock price (NASDAQ: ARNA)

Use our graph to track the performance of ARNA stocks over time.

Arena Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-10-24.

Latest market close	$60.35
52-week range	$45.50 - $90.19
50-day moving average	$60.40
200-day moving average	$61.85
Wall St. target price	$95.56
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-8.18

Buy Arena Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Arena Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Arena Pharmaceuticals price performance over time

Historical closes compared with the close of $60.35 from 2021-10-22

1 week (2021-10-14)	-5.32%
1 month (2021-09-24)	0.45%
3 months (2021-07-23)	-7.58%
6 months (2021-04-23)	-9.82%

1 year (2020-10-23)	-25.81%
2 years (2019-10-24)	23.42%
3 years (2018-10-24)	71.40%
5 years (2016-10-24)	3,695.60%

Is Arena Pharmaceuticals under- or over-valued?

Valuing Arena Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Arena Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Arena Pharmaceuticals's PEG ratio

Arena Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.46. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Arena Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Arena Pharmaceuticals's EBITDA

Arena Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $549.8 million.

The EBITDA is a measure of a Arena Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Arena Pharmaceuticals financials

Revenue TTM	$57,000
Gross profit TTM	$-323,421,000
Return on assets TTM	-26.32%
Return on equity TTM	-43.74%
Profit margin	0%
Book value	$15.91
Market capitalisation	$3.7 billion

TTM: trailing 12 months

Shorting Arena Pharmaceuticals shares

There are currently 2.5 million Arena Pharmaceuticals shares held short by investors – that's known as Arena Pharmaceuticals's "short interest". This figure is 5.6% up from 2.3 million last month.

There are a few different ways that this level of interest in shorting Arena Pharmaceuticals shares can be evaluated.

Arena Pharmaceuticals's "short interest ratio" (SIR)

Arena Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Arena Pharmaceuticals shares currently shorted divided by the average quantity of Arena Pharmaceuticals shares traded daily (recently around 499598.58585859). Arena Pharmaceuticals's SIR currently stands at 4.95. In other words for every 100,000 Arena Pharmaceuticals shares traded daily on the market, roughly 4950 shares are currently held short.

However Arena Pharmaceuticals's short interest can also be evaluated against the total number of Arena Pharmaceuticals shares, or, against the total number of tradable Arena Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Arena Pharmaceuticals's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Arena Pharmaceuticals shares in existence, roughly 40 shares are currently held short) or 0.0452% of the tradable shares (for every 100,000 tradable Arena Pharmaceuticals shares, roughly 45 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Arena Pharmaceuticals.

Find out more about how you can short Arena Pharmaceuticals stock.

Arena Pharmaceuticals share dividends

We're not expecting Arena Pharmaceuticals to pay a dividend over the next 12 months.

Have Arena Pharmaceuticals's shares ever split?

Arena Pharmaceuticals's shares were split on a 1:10 basis on 18 June 2017. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Arena Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Arena Pharmaceuticals shares which in turn could have impacted Arena Pharmaceuticals's share price.

Arena Pharmaceuticals share price volatility

Over the last 12 months, Arena Pharmaceuticals's shares have ranged in value from as little as $45.5 up to $90.19. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arena Pharmaceuticals's is 0.436. This would suggest that Arena Pharmaceuticals's shares are less volatile than average (for this exchange).

Arena Pharmaceuticals overview

Arena Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase I clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with Second Genome, Inc. ; United Therapeutics Corporation; Everest Medicines Limited; Beacon Discovery; Boehringer Ingelheim International GmbH; Eisai Co. , Ltd.

Frequently asked questions

What percentage of Arena Pharmaceuticals is owned by insiders or institutions?
Currently 0.298% of Arena Pharmaceuticals shares are held by insiders and 94.613% by institutions. How many people work for Arena Pharmaceuticals?
Latest data suggests 363 work at Arena Pharmaceuticals. When does the fiscal year end for Arena Pharmaceuticals?
Arena Pharmaceuticals's fiscal year ends in December. Where is Arena Pharmaceuticals based?
Arena Pharmaceuticals's address is: 136 Heber Avenue, Park City, UT, United States, 84060 What is Arena Pharmaceuticals's ISIN number?
Arena Pharmaceuticals's international securities identification number is: US0400476075 What is Arena Pharmaceuticals's CUSIP number?
Arena Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 040047102